Statement: Zantac (ranitidine) litigation
Issued: London, UK
For media and investors only
In response to yesterday’s Sargon ruling by the California state court in respect of the Goetz case, GSK plc (LSE/NYSE: GSK) today issued the following statement:
GSK respectfully disagrees with this ruling by the California state court. Following the 13 epidemiological studies conducted looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.
The litigation is still at an early stage and yesterday’s decision relates only to the question of whether the plaintiff's experts can testify at trial in the Goetz case. It does not mean that the Court agrees with plaintiff’s experts’ scientific conclusions or their litigation-driven science. GSK will press additional defences and the plaintiff still needs to prove his case at trial.
This ruling does not affect other state cases or the December 2022 Daubert ruling made in the federal Multi-District Litigation.
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com/company
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors” in the company's Annual Report on Form 20-F for 2022, GSK’s Q4 Results for 2022 and any impacts of the COVID-19 pandemic.